Safety and pharmacokinetic profile of multiple escalating doses of (+)-calanolide A, a naturally occurring nonnucleoside reverse transcriptase inhibitor, in healhy HIV-negative volunteers

HIV Clinical Trials

Volumn 3, Issue 6, 2002, Pages 435-450

  Eiznhamer, David A ^a   Creagh, Terri ^b   Ruckle, Jon L ^c   Tolbert, Dwain T ^d   Giltner, Jeremy ^a   Dutta, Bipul ^a   Flavin, Michael T ^a   Jenta, Tuah ^e   Xu, Ze Qi ^f  

^a DeCODE Chemistry & Biostructures   (United States)

^b Epidemiologic Consultant   (United States)

^c Northwest Kinetics   (United States)

^d QTEC   (United States)

^e Sarawak MediChem Pharm Inc   (United States)

^f Advanced Life Sciences Inc   (United States)

Author keywords

(+) calanolide A; HIV; NNRTI

Indexed keywords

ANTIVIRUS AGENT; CALANOLIDE A; PLACEBO; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DYSPHORIA; ERUCTATION; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INCIDENCE; LABORATORY TEST; MALE; MASTALGIA; MENSTRUATION DISORDER; MIGRAINE; MULTIPLE DRUG DOSE; NORMAL HUMAN; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SERODIAGNOSIS; STEADY STATE; VERTIGO;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; COHORT STUDIES; COUMARINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; PYRANOCOUMARINS; REFERENCE VALUES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0036867571     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/9GDE-F2R1-W2RL-E9FJ     Document Type: Article

References (15)

1. Kashman Y, Gustafson KR, Fuller RW, et al. The (+)-calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum. J Med Chem. 1992;35:2735-2743.
2. Xu ZQ, Flavin MT, Jenta TR. Calanolides, the naturally occurring anti-HIV agents. Curr Opin Drug Disc Dev. 2000;3:155-166.
3. Flavin MT, Rizzo JR, Khilevich A, et al. Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (±)-calanolide A and its enantiomers. J Med Chem. 1996;39:1303-1313.
4. Boyer PL, Currens MJ, McMahon JB, Boyd MR, Hughes SH. Analysis of non-nucleoside drug-resistant variants of human immunodeficiency virus Type 1 reverse transcriptase. J Virol. 1993;67:2412-2420.
5. Currens MJ, Gulakowski RJ, Mariner JM, et al. Antiviral activity and mechanism of action of (+)-calanolide A against the human immunodeficiency virus Type 1. J Pharmacol Exp Ther. 1996;279:646-651.
6. Buckheit RW Jr, White EL, Fliakas-Boltz, V, et al. Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide. Antimicrob Agents Chemother. 1999;43:1827-1834.
7. Buckheit RW Jr, Fliakas-Boltz V, Decker WD, et al. Comparative anti-HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups. Antiviral Res. 1995;26:117-132.
8. Quan Y, Motakis D, Buckheit R Jr, et al. Sensitivity and resistance to (+)-calanolide A of wild type and mutated forms of HIV-1 reverse transcriptase. Antiviral Ther. 1999;4:203-209.
9. Hizi A, Tal R, Shaharabany M, et al. Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors. Antimicrob Agents Chemother. 1993;37:1037-1042.
10. Xu ZQ, Hertogs K, Van den Eynde CH, Bloor S, Larder B, Dutta B. In vitro phenotypic resistance profile of (+)-calanolide A, a naturally occurring NNRTI, against clinical isolates of HIV-1 with Y181C mutation. In: Program and abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 26-29, 1999; San Francisco, California. Abstract No. 440.
11. Currens MJ, Mariner JM, McMahon JB, Boyd MR. Kinetic analysis of inhibition of human immunodeficiency virus type 1 reverse transcriptase by (+)-calanolide A. J Pharmacol Exp Ther. 1996;279:652-661.
12. Frank P, Flavin MT, Roca-Acin J, Xu ZQ. Safety assessment of (+)-calanolide A, a naturally occurring anti-HIV agent. In: Program and abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections; January 22-26, 1997; Washington, DC. Abstract No. 225.
13. Creagh T, Ruckle JL, Tolbert DT, et al. Safety and pharmacokinetics of single doses of (+)-calanolide A, a novel, naturally-occurring non-nucleoside reverse transcriptase inhibitor, in healthy, HIV-negative humans. Antimicrob Agents Chemother. 2000;45:1379-1386.
14. Patil SD, Thilagar AK, Frank P, Xu ZQ. In vitro biotransformation of (+)-calanolide A by cytochrome P-450 enzymes [abstract]. Pharm Sci. 1998;S1:S-41.
15. Fiske WD, Benedek IH, Joshi AS, Joseph JL, Kornhauser DM. Summary of pharmacokinetic drug interaction studies with efavirenz. In: Program and abstracts of the 36th Annual Meeting of the Infectious Diseases Society of America; November 12-15, 1998; Denver, Colorado. Abstract 46.